Canary Speech to Play a Role in Alzheimers Drug Development

Halia Therapeutics, a pharmaceutical company developing neuroinflammation-targeting drugs, and Canary Speech, a provider of artificial intelligence vocal biomarker technology, are partnering to revolutionize the way Alzheimer's disease can be monitored and treated.

This collaboration leverages Canary Speech's AI vocal biomarker platform to analyze subtle changes in voice patterns and monitor cognitive function changes in Alzheimer's patients. Halia will integrate these insights to enhance the development and efficacy of its new Alzheimer's drug.

"This collaboration is a significant step forward in our mission to address the challenges of Alzheimer's disease and advance the clinical development of HT-4253, which targets a unique component of neuro-inflammation," said David Bearss, CEO of Halia Therapeutics, in a statement. "Canary AI-driven speech technology will provide invaluable data to help us tailor our therapies more effectively and improve outcomes for patients with this debilitating neurodegenerative disease."

"We are thrilled to be combining our pioneering AI technology with Halia's expertise in drug development targeting neuro-inflammation," said Henry O'Connell, CEO and co-founder of Canary Speech, in a statement. "Our goal is to transform Alzheimer's patient care and provide a more nuanced understanding of how treatments impact cognitive function over time."